Evidence map›Paper›PMID 24048788›Full record

ArticleCancer2011

Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Zhimin Tong, Subhankar Chakraborty, Bokyung Sung, Pooja Koolwal, Sukhwinder Kaur, Bharat B Aggarwal, Sendurai A Mani, Robert S Bresalier, Surinder K Batra, Sushovan Guha

Abstract read
In one paragraph

Article in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Lipocalin-2 expression and function in pancreatic diseases.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2020
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhimin TongDepartment of Gastroenterology, Hepatology, and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Subhankar Chakraborty
Bokyung Sung
Pooja Koolwal
Sukhwinder Kaur
Bharat B Aggarwal
Sendurai A Mani
Robert S Bresalier
Surinder K Batra
Sushovan Guha
The University of Texas MD Anderson Cancer Center · USUniversity of Nebraska Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
MUCIN GLYCOPROTEINS IN COLON CANCER METASTASISR01CA069480 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BRESALIER, ROBERT S · 1996 to 2010
$2.6M
MOLECULAR STUDIES ON MUC4 MUCIN GENER01CA078590 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 1998 to 2011
$2.5M
NCI NIH HHS 5P30CA16672NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA069480NCI NIH HHS R01 CA078590NCI NIH HHS R01 CA69480NCI NIH HHS R01 CA78590
6 · The paper itself

Abstract

backgroundThe authors previously reported that neutrophil gelatinase-associated lipocalin (NGAL) overexpression significantly blocked invasion and angiogenesis of pancreatic ductal adenocarcinoma (PDAC). They also demonstrated a loss of NGAL expression in the advanced stages of PDAC. However, little is known regarding the mechanisms of NGAL regulation in PDAC. Because the epidermal growth factor (EGF)-EGF receptor (EGFR) axis is up-regulated significantly in PDAC, they examined EGF-mediated NGAL regulation in these cells.

methodsThe NGAL-positive cell lines AsPC-1 and BxPC-3 were used as a model system. Quantitative real-time polymerase chain reaction (RT-PCR), Western blot analysis, and immunofluorescence studies were used to investigate EGF-mediated effects on NGAL expression. E-cadherin expression was manipulated using lentiviral overexpression or small hairpin RNA constructs. NGAL promoter activity was assessed by luciferase-reporter assay and electrophoretic mobility shift assay.

resultsNGAL expression was positively associated with tumor differentiation and was down-regulated significantly after EGF treatment along with a concomitant reduction of E-cadherin expression in PDAC cells. E-cadherin down-regulation was partly through the EGFR-dependent mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) (MEK-ERK) signaling pathway. In addition, E-cadherin down-regulation reduced NGAL expression in PDAC cells, whereas overexpression of E-cadherin led to increased NGAL expression and partly rescued the inhibition of NGAL expression by EGF. Furthermore, EGF, in part through E-cadherin, reduced NGAL promoter activity by blocking nuclear factor κB (NF-κB) activation.

conclusionsThe current study demonstrated for the first time that EGF potently blocked NGAL expression in PDAC cells. This effect was mediated in part through activation of the EGFR-MEK-ERK signaling pathway, which, in turn, down-regulated E-cadherin with a subsequent reduction in NF-κB activation. These findings illustrate a novel mechanism by which EGF regulates NGAL expression in PDAC.

Indexed as

Acute-Phase ProteinsCadherinsCell Line, TumorEpidermal Growth FactorExtracellular Signal-Regulated MAP KinasesGene Expression Regulation, NeoplasticHumansLipocalin-2LipocalinsNeoplasm GradingNeoplasm StagingNF-kappa BPancreatic NeoplasmsProto-Oncogene ProteinsSignal TransductionAcute-Phase ProteinsCadherinsEpidermal Growth FactorExtracellular Signal-Regulated MAP KinasesLCN2 protein, humanLipocalin-2LipocalinsNF-kappa BProto-Oncogene ProteinsE-cadherinepidermal growth factorneutrophil gelatinase associated lipocalinnuclear factor κBpancreatic cancer

Identifiers

PMID24048788
PMCPMC3134548
OpenAlexW1986692800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.